Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Crit Rev Oncol Hematol ; 114: 77-90, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28477749

ABSTRACT

Gestational trophoblastic diseases (GTD) encompass a group of placental tumors which mostly arise due to certain fertilization defects, resulting in the over-proliferation of trophoblasts. The major characteristic of this diseased state is that ß-hCG rises up manifold than that is observed during pregnancy. The incidence of GTD when analyzed on a global scale, figures out that there is a greater risk in South-East Asia, the reason of which remains unclear. An insight into any possible correlation of GTD incidence with cancers, other than choriocarcinoma, is being attempted here. Also, we review the recent developments in research on the molecular etiopathology of GTD. This review would render a wider eye towards a new paradigm of thoughts to connect GTD and breast cancer, which has not been into the picture till date.


Subject(s)
Gestational Trophoblastic Disease/complications , Neoplasms/etiology , Female , Gestational Trophoblastic Disease/epidemiology , Humans , Incidence , Neoplasms/epidemiology , Pregnancy , Prognosis
2.
Crit Rev Oncol Hematol ; 101: 184-92, 2016 May.
Article in English | MEDLINE | ID: mdl-27017408

ABSTRACT

The identification of various biomolecules in cancer progression and therapy has led to the exploration of the roles of two cardinal players, namely Nitric Oxide (NO) and Reactive Oxygen Species (ROS) in cancer. Both ROS and NO display bimodal fashions of functional activity in a concentration dependent manner, by inducing either pro- or anti- tumorigenic signals. Researchers have identified the potential capability of NO and ROS in therapies owing to their role in eliciting pro-apoptotic signals at higher concentrations and their ability to sensitize cancer cells to one another as well as to other therapeutics. We review the prospects of NO and ROS in cancer progression and therapy, and analyze the role of a combinatorial therapy wherein an NO donor (SNAP) is used to sensitize the oxidative damage repair defective, triple negative breast cancer cells (HCC 1937) to a potent ROS inducer. Preliminary findings support the potential to employ various combinatorial regimes for anti-cancer therapies with regard to exploiting the chemo-sensitization property of NO donors.


Subject(s)
Breast Neoplasms/metabolism , Nitric Oxide/metabolism , Reactive Oxygen Species/metabolism , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Humans , Neoplastic Stem Cells/metabolism , Oxidation-Reduction
SELECTION OF CITATIONS
SEARCH DETAIL
...